This mob is always on target to roll something out… The problem...

This mob is always on target to roll something out… The problem is they have no ability to understand US healthcare reimbursement market, identify the right partners and strategically align their pricing to take these products to the masses at sensible margins. Floating more shares, burning a lot of cash and big-name partnerships that continue to deliver very disappointing results given the structure of these one-way street deals that don’t favor bloody NXS or the shareholders. The Managing Director Judith Mitchell has to go but she’s in cahoots too deep with the walker group and unfortunately the board is controlled by these entities to a fault. It is what’s it is so I understand that the technology is for real but the management team trying to deliver the results is not. Still holding firm on the price target of $.50 as that is where I value the IP. As always do your due diligence. Cheers.